Nitazene Dependence Causes Real Withdrawal. Standard Buprenorphine Doses May Fall Short.

Clinical Scenario

A 22-year-old man with no history of opioid use presents to the emergency department in opioid withdrawal after vaping a product sold online as a cannabinoid; standard-dose buprenorphine fails to control his symptoms. Toxicology later confirms protonitazene in both his blood and the vape liquid.

The Pearl

Nitazenes are benzimidazole synthetic opioids whose potency can exceed fentanyl, and regular use can produce a genuine physical dependence with a withdrawal syndrome that frontline protocols were not built to treat. A 2026 case report described exactly this: a previously opioid naive young man whose chronic protonitazene vaping led to dependence, then **required buprenorphine doses higher than standard induction levels call for, plus adjunctive diazepam and olanzapine, before withdrawal was controlled.**1

This matters because a routine induction or taper calibrated for heroin, oxycodone, or fentanyl withdrawal may leave a nitazene-dependent patient undertreated and at high risk of returning to an unpredictable illicit supply.

Why It Matters

A New South Wales surveillance cohort identified 27 laboratory-confirmed nitazene exposures over nearly seven years: 20 were unintentional poisonings, and **7 presented in acute withdrawal, a pattern the authors flagged as a novel clinical observation.**2 Vaping was the most common route, and protonitazene, protonitazepyne, and isotonitazene were the most frequently detected compounds; patients, and even their suppliers, may not know nitazenes are present at all.

A parallel review found no published studies on methadone, buprenorphine, or naltrexone effectiveness specifically in nitazene-dependent patients, leaving clinicians to extrapolate from protocols not built for this potency class.3 Missing this risks undertreated withdrawal and a faster return to use.

Bottom Line: If a patient reports vaping or using a product they did not know contained nitazenes and presents in withdrawal that is not responding to a standard buprenorphine dose, escalate dosing and add adjunctive medication early rather than waiting for a slow taper to catch up.

References

1. Dutkiewicz D, Wilson H, Jiranantakan T, Chisholm P, Fatema K, Hardy M. Management of opioid withdrawal syndrome and commencement of opioid dependence treatment following chronic use of a vaping product containing protonitazene: case report. *Drug Alcohol Rev.* 2026;45(1):e70104.

2. Roberts DM, Tisdell B, Sajeev MF, Jiranantakan T, Harvey C, Brown JA. Clinical experiences with the nitazene class of synthetic opioids: a cohort study. *Ann Emerg Med.* 2025;86(5):475-483.

3. Nielsen S, Silva JP, Jones JD, et al. Behavioural effects and naloxone effectiveness with new synthetic opioids. *Drug Alcohol Rev.* 2025;45(1):e70040.

William L. Bundy Jr., PharmD | ToxiPharm LLC | toxipharm@toxipharm.org

DISCLAIMER: This document is intended for clinical reference and educational purposes only for use by licensed healthcare professionals. It does not constitute medical advice and should not replace independent clinical judgment. Content reflects published data available at time of preparation. ToxiPharm LLC makes no warranties regarding completeness or applicability in all clinical situations. © 2026 ToxiPharm LLC | toxipharm.org | toxipharm@toxipharm.org

 © 2026 ToxiPharm LLC. All rights reserved.